Oakworth Capital’s Nektar Therapeutics NKTR Stock Holding History

Oakworth Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12	Closed	-$3K	–	582
2020 Q1	$3K	Buy	+12	New	+$3.71K	﹤0.01%	470

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Oakworth Capital's NKTR Position: Q2 2020 in Review

Oakworth Capital sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 12 shares — an estimated $3K sold.

Oakworth Capital first reported a position in NKTR in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

Oakworth Capital reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
Oakworth Capital sold 12 Nektar Therapeutics shares in Q2 2020, an estimated $3K.
Oakworth Capital first reported a position in Nektar Therapeutics in Q1 2020 and held it in 1 quarter.
Oakworth Capital's Nektar Therapeutics position peaked at $3K in Q1 2020.
260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on Oakworth Capital's 13F filing for Q2 2020, filed 11 Aug 2020.